Weight-Loss Medication for Children: Ozempic and Wegovy by Novo Nordisk
Weight-Loss Medication Insights
Weight-loss medication is becoming a viable option for younger populations with Novo Nordisk's Ozempic and Wegovy leading the charge. Studies suggest that these medications can help manage obesity in children as young as 6 years old.
Regulatory Advances
In the United States, Novo Nordisk has requested regulatory approval for these medications targeted towards children aged 6 to 11. Meanwhile, in Europe, adolescents have already been given access to these treatments at the age of 12 and above.
Implications on Pediatric Health
iThe implications for pediatric health are significant, as childhood obesity rates continue to rise. With these medications, children may find a new avenue for weight management that supports healthier outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.